The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Johanna C. Bendell
No relevant relationships to disclose
Thomas J. Ervin
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Donald A. Richards
No relevant relationships to disclose
Irfan Firdaus
No relevant relationships to disclose
A. Craig Lockhart
Research Funding - Keryx
Allen Lee Cohn
No relevant relationships to disclose
Mansoor N. Saleh
Research Funding - Keryx
Lesa R. Gardner
Employment or Leadership Position - Keryx
Stock Ownership - Keryx
Peter Sportelli
Employment or Leadership Position - Keryx
Stock Ownership - Keryx
Cathy Eng
Honoraria - Amgen; Bayer; Genentech
Research Funding - Amgen; Daiichi Sankyo; Keryx